42
Participants
Start Date
November 4, 2024
Primary Completion Date
October 31, 2026
Study Completion Date
November 30, 2026
Rivastigmine
Rivastigmine 3mg by mouth once, followed by rivastigmine 1.5mg by mouth every 1 hour as needed for ongoing delirium or agitation (at the discretion of the treating physician), for a maximum of three doses
Placebo
Matching oral placebo by mouth once, followed by placebo by mouth every 1 hour as needed for ongoing delirium or agitation (at the discretion of the treating physician), for a maximum of three doses
RECRUITING
Washington University School of Medicine, St Louis
American Academy of Clinical Toxicology
OTHER
Washington University School of Medicine
OTHER